SCHEMBL2903263

SCHEMBL2903263

Fc1ccc(-c2ccc(-n3cc(CN4CCOCC4)c(-c4ccco4)n3)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.48
KDM4E B2RXH2 6/20 0.48
NPC1 O15118 1/20 0.48
MAPT P10636 1/20 0.48
NPSR1 Q6W5P4 3/20 0.46
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 4/20 0.46
POLB P06746 3/20 0.46
LMNA P02545 2/20 0.44
GAA P10253 2/20 0.44
TSHR P16473 1/20 0.44
KMT2A Q03164 1/20 0.44
SLC2A1 P11166 1/20 0.43
SSTR5 P35346 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
SLC2A3 P11169 1/20 0.40
SLC2A4 P14672 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2902611 0.91 ALDH1A1 (0.53) ALDH1A1KDM4ENPC1MAPTNPSR1
SCHEMBL2904839 0.89 NPSR1 (0.52) ALDH1A1KDM4ENPC1MAPTNPSR1
SCHEMBL2908994 0.87 ALDH1A1 (0.52) ALDH1A1KDM4ENPC1MAPTPOLB
SCHEMBL2902823 0.87 ALDH1A1 (0.64) ALDH1A1KDM4ENPC1MAPTNPSR1
SCHEMBL2904990 0.85 KDM4E (0.55) ALDH1A1KDM4ENPC1MAPTNPSR1
SCHEMBL2909330 0.85 ALDH1A1 (0.54) ALDH1A1KDM4ENPC1MAPTNPSR1
SCHEMBL2905976 0.85 ALDH1A1 (0.54) ALDH1A1KDM4ENPC1MAPTNPSR1
SCHEMBL2907733 0.83 ALDH1A1 (0.47) ALDH1A1KDM4ENPC1MAPTNPSR1
Morpholine SCHEMBL2905728 0.83 ALDH1A1 (0.49) ALDH1A1KDM4ENPC1MAPTNPSR1
SCHEMBL2903064 0.81 ALDH1A1 (0.52) ALDH1A1KDM4ENPC1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP disclosed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A ALDH1A1 1336/4885KDM4E 3489/4885NPC1 1748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.